Cabometyx
Cabometyx Shows Dramatic Benefits in Advanced Neuroendocrine Tumors (ESMO 2023)
Anika Sharma
ESMO 2023: LBA53 Exelixis made headlines last month when its Cabometyx exceeded expectations in the treatment of neuroendocrine tumors (NETs), ...
Exelixis Celebrates Early End to Cabometyx Trial for Neuroendocrine Tumors due to Remarkable Efficacy
Anika Sharma
Exelixis, a drug developer, recently halted a cancer trial involving Cabometyx, their tyrosine kinase inhibitor, due to an overwhelming display ...
Resilient Triumph: Roche and Exelixis’ Tecentriq-Cabometyx Combination Shows Promise in Advanced Prostate Cancer After Past Challenges
Anika Sharma
After facing setbacks in clinical trials, the combination of Roche’s Tecentriq and Exelixis’ Cabometyx has achieved a breakthrough in treating ...
Cabometyx patent battle is resolved by Exelixis and Teva with a 2031 generic license
SG Tylor
Source – Exelixis Exelixis, the company behind the successful cancer drug Cabometyx, has been actively defending its intellectual property. In ...
